An optimized prediction framework to assess the functional impact of pharmacogenetic variants
暂无分享,去创建一个
Yitian Zhou | Souren Mkrtchian | Masaki Kumondai | Masahiro Hiratsuka | Volker M Lauschke | Yitian Zhou | V. Lauschke | M. Hiratsuka | S. Mkrtchian | Masaki Kumondai | Masaki Kumondai
[1] H. Carter,et al. Identifying Mendelian disease genes with the Variant Effect Scoring Tool , 2013, BMC Genomics.
[2] C. Sander,et al. Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.
[3] Masamitsu Maekawa,et al. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. , 2015, Drug metabolism and pharmacokinetics.
[4] Charles Swanton,et al. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine , 2014, Genome Biology.
[5] B. Fernandez,et al. Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care , 2015, Clinical genetics.
[6] M. Ingelman-Sundberg,et al. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response , 2016, Genetics in Medicine.
[7] M. Hiratsuka,et al. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. , 2014, Drug metabolism and pharmacokinetics.
[8] Nidhi Mathur,et al. Computational approaches for predicting mutant protein stability , 2016, Journal of Computer-Aided Molecular Design.
[9] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[10] Thomas A. Peterson,et al. Towards precision medicine: advances in computational approaches for the analysis of human variants. , 2013, Journal of molecular biology.
[11] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[12] Patrick F Sullivan,et al. The genomics of schizophrenia: update and implications. , 2013, The Journal of clinical investigation.
[13] Masahiro Hiratsuka,et al. Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57) , 2008, Drug Metabolism and Disposition.
[14] Xiaohui Xie,et al. Identifying novel constrained elements by exploiting biased substitution patterns , 2009, Bioinform..
[15] Justin C. Fay,et al. Identification of deleterious mutations within three human genomes. , 2009, Genome research.
[16] J. Reis-Filho,et al. Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations , 2014, Genome Biology.
[17] K. Pollard,et al. Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.
[18] David M. W. Powers,et al. Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation , 2011, ArXiv.
[19] Daniel J. Park,et al. Variant effect prediction tools assessed using independent, functional assay-based datasets: implications for discovery and diagnostics , 2017, Human Genomics.
[20] D. Haussler,et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. , 2005, Genome research.
[21] Melissa A. Basford,et al. Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.
[22] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[23] Andrea Gaedigk,et al. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. , 2003, Clinical chemistry.
[24] Claudio J. Verzilli,et al. An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People , 2012, Science.
[25] R. Gibbs,et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.
[26] Bartha Maria Knoppers,et al. Population genetic testing for cancer susceptibility: founder mutations to genomes , 2016, Nature Reviews Clinical Oncology.
[27] B. Taylor,et al. Implementing Genome-Driven Oncology , 2017, Cell.
[28] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[29] S. Henikoff,et al. Predicting the effects of amino acid substitutions on protein function. , 2006, Annual review of genomics and human genetics.
[30] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[31] Masamitsu Maekawa,et al. Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities , 2017, Drug Metabolism and Disposition.
[32] Hua Xu,et al. A comparative study of disease genes and drug targets in the human protein interactome , 2015, BMC Bioinformatics.
[33] Kenneth Offit,et al. Genome-wide association studies of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Mark I McCarthy,et al. Genomics, type 2 diabetes, and obesity. , 2010, The New England journal of medicine.
[35] Tom R. Gaunt,et al. Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.
[36] Colin Campbell,et al. An integrative approach to predicting the functional effects of non-coding and coding sequence variation , 2015, Bioinform..
[37] O. Lichtarge,et al. Predicting phenotype from genotype: Improving accuracy through more robust experimental and computational modeling , 2017, Human mutation.
[38] Xiaohui Xie,et al. DANN: a deep learning approach for annotating the pathogenicity of genetic variants , 2015, Bioinform..
[39] Anthony J. Kusalik,et al. Computational prediction of eukaryotic phosphorylation sites , 2011, Bioinform..
[40] M. Vihinen,et al. Performance of mutation pathogenicity prediction methods on missense variants , 2011, Human mutation.
[41] S. Henikoff,et al. Predicting deleterious amino acid substitutions. , 2001, Genome research.
[42] M. Ingelman-Sundberg,et al. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects , 2012, The Pharmacogenomics Journal.
[43] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[44] M. Ingelman-Sundberg,et al. Genetic variation in the human cytochrome P450 supergene family , 2015, Pharmacogenetics and genomics.
[45] Jeffrey P. Jones,et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.
[46] Trevor Hastie,et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.
[47] M. Ingelman-Sundberg,et al. Precision Medicine and Rare Genetic Variants. , 2016, Trends in pharmacological sciences.
[48] L. Milani,et al. Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments , 2017, The AAPS Journal.
[49] K. Boycott,et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.
[50] Serafim Batzoglou,et al. Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..